Harmony Biosciences Q1 revenue up 17% to $215.4 million; 2026 guidance reiterated
Harmony Biosciences reported first-quarter 2026 WAKIX net product revenue of $215.4 million, up 17% from $184.7 million a year earlier, and reiterated its 2026 net revenue guidance of $1.0 billion to $1.04 billion. Net income fell to $32.5 million, or $0.55 per diluted share, from $45.6 million, or $0.78, because of $32.0 million in up-front license payments recorded in research and development expenses. Revenue grew while profit declined, so the quarter shows mixed results for shareholders.
Key points
- Net product revenue was $215.4 million for the quarter ended March 31, 2026, compared with $184.7 million a year earlier; average patients were 8,500 in Q1.
- Net income was $32.5 million, or $0.55 per diluted share, versus $45.6 million, or $0.78, in Q1 2025.
- Research and development expenses rose to $69.4 million from $34.5 million, including $32.0 million in up-front license payments; cost of product sold rose to 20.7% of net product revenue from 17.3%.
- 2026 WAKIX net revenue guidance was reiterated at $1.0 billion to $1.04 billion; cash, cash equivalents and investments were $870.5 million as of March 31, 2026.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:55 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.